Lingeba Technology

Lingeba Technology is a clinical-stage biotechnology company focused on developing innovative T-cell receptor (TCR-T) therapies for the treatment of solid tumors. Leveraging its proprietary high-affinity TCR discovery and optimization platform, the company identifies and engineers T cells to target intracellular tumor-associated antigens that are typically inaccessible to conventional antibody-based therapies. Its lead candidate, LGB-001, is currently in Phase 1 clinical trials for hepatocellular carcinoma, targeting the alpha-fetoprotein (AFP) antigen. Lingeba is backed by prominent venture capital firms including GL Ventures and Matrix Partners China. The company maintains a robust pipeline of TCR-T programs targeting various solid tumor indications such as NY-ESO-1 and PRAME. Lingeba aims to overcome the limitations of current cell therapies in the immunosuppressive solid tumor microenvironment.